Search results for "Logo"

showing 10 items of 1128 documents

Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients

2009

Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these da…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentbone marrow transplantationContext (language use)myelofibrosisHematopoietic stem cell transplantationKaplan-Meier EstimateSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalYoung AdultPharmacotherapyInternal medicinemedicineHumansTransplantation HomologousYoung adultMyelofibrosisRetrospective Studiesbusiness.industryAge FactorsHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationmyelofibrosis; bone marrow transplantationPrimary MyelofibrosisFemaleTransplantation ConditioningbusinessFollow-Up Studies
researchProduct

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term foll…

2010

Background Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. Design and Methods The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen w…

AdultMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentFollicular lymphomaHematopoietic stem cell transplantationGastroenterologyreduced intensity conditioningfollicular lymphomaallogeneic stem cell transplantationInternal medicinemedicinegraft-versus-host diseaseHumansTransplantation HomologousLymphoma FollicularSurvival ratebusiness.industryHistocompatibility TestingSiblingsHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseSurgeryFludarabineSurvival RateTransplantationTreatment OutcomeGraft-versus-host diseaseFemaleOriginal ArticleTransplantation ConditioningbusinessProgressive diseaseFollow-Up Studiesmedicine.drugHLA identical sibling donor
researchProduct

Comparison of intermittent- and continuous-flow cell separators for the collection of autologous peripheral blood progenitor cells in patients with h…

2001

BACKGROUND: The transplantation of autologous peripheral blood progenitor cells (PBPCs) after high-dose chemotherapy is a valuable therapy for patients with hematologic and solid malignancies. Several methods are used for harvesting PBPCs. The efficiency of intermittent- and continuous-flow blood cell separators in collecting progenitor cells from the blood of patients undergoing myeloablative treatment for cancer was compared. STUDY DESIGN AND METHODS: PBPC components (n = 133) were obtained from 72 patients by leukapheresis with continuous-flow machines (Spectra, COBE; CS 3000 Plus, Baxter) and with an intermittent-flow machine (MCS 3P, Haemonetics). The data were analyzed retrospectively…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentImmunologyUrologyCD34Blood volumeAntigens CD34Cell SeparationTransplantation AutologousBlood cellmedicineImmunology and AllergyHumansPlateletLeukapheresisProgenitor cellRetrospective StudiesChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyLeukapheresisMiddle AgedHematopoietic Stem CellsSurgeryBlood Cell CountTransplantationmedicine.anatomical_structureHematologic NeoplasmsFemalebusinessTransfusion
researchProduct

Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplan…

2004

International audience; Background. Isolated case reports have shown that recipients of allogeneic hematopoietic stem cell transplants ( HSCTs) who develop toxoplasmosis may have circulating Toxoplasma gondii DNA in peripheral blood before the onset of clinical symptoms. Methods. We prospectively studied 106 T. gondii - seropositive adult recipients of HSCTs for the incidence of reactivation of toxoplasmosis in the first 6 months after transplantation. Toxoplasmosis infection ( TI) was defined by a positive result of polymerase chain reaction ( PCR) of peripheral blood specimens, whereas toxoplasmosis disease ( TD) was defined as an invasive infection. Results. The incidence of TI was 16% (…

AdultMicrobiology (medical)POLYMERASE-CHAIN-REACTIONmedicine.medical_treatment[SDV]Life Sciences [q-bio]Hematopoietic stem cell transplantationPolymerase Chain ReactionParasite loadCYTOMEGALOVIRUS-INFECTIONBlood cell03 medical and health sciencesIMMUNE RECONSTITUTION0302 clinical medicinemedicineAnimalsHumansTransplantation Homologous030212 general & internal medicineREAL-TIME PCR0303 health sciencesHematologic Testsbiology030306 microbiologybusiness.industryIncidence (epidemiology)Toxoplasma gondiiDNA Protozoanbiology.organism_classificationmedicine.diseaseBONE-MARROW-TRANSPLANTATIONPREEMPTIVE THERAPYToxoplasmosis3. Good healthTransplantationRECIPIENTSInfectious DiseasesReal-time polymerase chain reactionmedicine.anatomical_structureImmunologySTATISTICAL-METHODSTRANSFER HYBRIDIZATION PROBESbusinessToxoplasmaToxoplasmosisStem Cell Transplantation
researchProduct

Repair of the mandibular nerve by means of autologous nerve grafting after resection of the lower jaw

1973

Summary On the basis of two cases we demonstrate our method of autologous nerve grafting for substitution of the mandibular nerve after mandibular resection. The sural nerve served as a donor nerve, the graft was imbedded microsurgically at the juncture points by means of a perineurial interfascicular nerve suture. Oversized grafts of about 20 cm in length were chosen intentionally in order to insert them without tension between the stumps of the recipient nerve and outside the regeneration zone of the bone. In both cases complete resensibilization of the lower lip was reached after about six months.

AdultMicrosurgerymedicine.medical_specialtyMandibular NerveMandibular nerveLower lipSural nerveTransplantation AutologousResectionAmeloblastomaPostoperative ComplicationsSural Nervestomatognathic systemmedicineHumansParesthesiaChildNerve graftingbusiness.industryGeneral MedicineAnatomyDenervationMandibular resectionLipNerve RegenerationOsteotomySurgeryMandibular Neoplasmssurgical procedures operativeFemaleSurgeryEpineurial repairNerve suturebusinessJournal of Maxillofacial Surgery
researchProduct

Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation fo…

2005

Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted. Therefore, we have designed a prospective phase II trial in CML, which, for the first time, evaluated the feasibility and safety of molecular end points as surrogate markers to guide through a stratified treatment algorithm within a multicenter trial. Patients and Methods As a clinical model, we adopted minimal residual disease (MRD) found in relapse after allogeneic stem cell transplantation (SCT) in CML. For…

AdultOncologyCancer Researchmedicine.medical_specialtyTime FactorsMaximum Tolerated Dosemedicine.drug_classFusion Proteins bcr-ablGraft vs Host DiseaseAntineoplastic AgentsPolymerase Chain ReactionPiperazinesTyrosine-kinase inhibitorMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesMulticenter trialInternal medicinemedicineHumansTransplantation HomologousProspective Studiesbusiness.industryRemission InductionImatinibProtein-Tyrosine Kinasesmedicine.diseaseMinimal residual diseaseTransplantationPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesImmunologyImatinib MesylateFeasibility StudiesbusinessStem Cell Transplantationmedicine.drugChronic myelogenous leukemiaJournal of Clinical Oncology
researchProduct

Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied

1998

High-dose chemotherapy with autologous transplantation of in vivo purged PBSC is a novel investigational approach to treating chronic myelogenous leukemia (CML) patients not responsive to conventional therapy with interferon-alpha (IFN-alpha) and not eligible for allogeneic transplantation. PBSC mobilization using either '5+2/7+3'-type chemotherapy or 'mini-ICE/ ICE' chemotherapy was investigated in 43 patients with advanced phases of Philadelphia (Ph)-positive CML. Thirty patients were in late chronic phase (12 months post diagnosis) and 13 patients in accelerated phase (AP) or blast crisis (BC). Contamination with Ph-positive cells was evaluated in harvests from 37/43 patients. The outcom…

AdultOncologymedicine.medical_specialtyTime FactorsAllogeneic transplantationmedicine.medical_treatmentPilot ProjectsCarboplatinCohort StudiesLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationIfosfamideEtoposideChemotherapyMobilizationHematologybusiness.industryHematologyGeneral MedicineLeukapheresisMiddle Agedmedicine.diseaseHematopoietic Stem Cell MobilizationSurgeryTreatment OutcomeBlast CrisisComplicationbusinessChronic myelogenous leukemiaAnnals of Hematology
researchProduct

Current results on the use of imatinib mesylate in patients with relapsed philadelphia chromosome positive leukemia after allogeneic or syngeneic hem…

2003

Here, we describe a patient diagnosed with chronic myelogenous leukemia who relapsed after matched unrelated donor SCT. The patient was treated with imatinib mesylate and donor lymphocyte infusions, and achieved a complete molecular remission. Additionally, safety and efficacy of imatinib mesylate in a total of 134 patients from 8 centers who underwent allogeneic or syngeneic stem cell transplantation (SCT) and had a relapse of Philadelphia chromosome positive leukemia was reviewed. Data was compiled from abstracts accepted as oral or poster presentations at the ASH (American Society of Hematology) 2001 and EBMT (European Group for Blood and Marrow Transplantation) 2001 & 2002 meetings and …

AdultOncologymedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationAntineoplastic AgentsHematopoietic stem cell transplantationPolymerase Chain ReactionPiperazinesRecurrenceLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansTransplantation Homologouseducationeducation.field_of_studyHematologybusiness.industryHematopoietic Stem Cell TransplantationGeneral Medicinemedicine.diseaseSurgerySyngeneic stem cell transplantationTransplantationTransplantation IsogeneicLeukemiaPyrimidinesTreatment OutcomeImatinib mesylateBenzamidesImatinib MesylateFemalebusinessChronic myelogenous leukemiaThe Keio Journal of Medicine
researchProduct

VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab

2008

AIM: To gain mechanistic insights into the role played by epidermal growth factor receptor (EGFR) in the regulation of vascular endothelial growth factors (VEGFs) in colorectal cancer (CRC). METHODS: The impact of high-level expression of the growth factor receptors EGFR and VEGF receptor (VEGFR)3 and the VEGFR3 ligands VEGF-C and VEGF-D on disease progression and prognosis in human CRC was investigated in 108 patients using immunohistochemistry. Furthermore, the expression of the lymphangiogenic factors in response to the modulation of EGFR signalling by the EGFR-targeted monoclonal antibody cetuximab was investigated at the mRNA and protein level in human SW480 and SW620 CRC cell lines an…

AdultPathologymedicine.medical_specialtyColorectal cancerTransplantation HeterologousVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DCetuximabAntineoplastic AgentsMice SCIDAntibodies Monoclonal HumanizedMiceGrowth factor receptorMice Inbred NODCell Line TumorMedicineAnimalsHumansEpidermal growth factor receptorneoplasmsAgedColorectal CancerAged 80 and overCetuximabbiologyintegumentary systembusiness.industryGastroenterologyVascular Endothelial Growth Factor DAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseVascular Endothelial Growth Factor Receptor-3digestive system diseasesLymphangiogenesisErbB ReceptorsVascular endothelial growth factor CCancer researchbiology.proteinImmunohistochemistryFemalebusinessColorectal NeoplasmsNeoplasm Transplantationmedicine.drugSignal Transduction
researchProduct

Salvage (tertiary) breast reconstruction after implant failure

2011

Summary Background Salvage breast reconstruction is defined as a complete revision of a previous reconstruction in case of unsatisfactory results or failure of primary or secondary breast reconstruction. We have termed this ‘tertiary breast reconstruction'. This article presents our experience with tertiary reconstructions, including the indications, method of reconstruction and outcomes. Methods A retrospective note review was performed for all patients who underwent breast reconstruction with autologous tissue under one surgeon between 2002 and 2009 at the University Hospital, Ghent. Out of these 688 patients, 54 patients (7.8%) required tertiary surgery with autologous tissue after failu…

AdultReoperationReconstructive surgerymedicine.medical_specialtyComplicationsmedicine.medical_treatmentBreast ImplantsMammaplastySettore MED/19 - Chirurgia PlasticaSalvage therapyDIEPTransplantation AutologousTertiary breast reconstructionlaw.inventionlawRisk FactorsmedicineHumansMastectomyRetrospective StudiesSalvage TherapyRadiotherapybusiness.industryAutologous tissueGraft SurvivalImplant failureImplant failureMiddle AgedSurgeryTreatment OutcomeMammaplastyBreast implantSurgeryFemaleImplantBreast reconstructionbusinessComplicationMastectomy
researchProduct